Starjemza

Drug Overview

STARJEMZA (ustekinumab-hmny) is a high-potency BIOLOGIC and a foundational IMMUNOMODULATOR within the IMMUNOLOGY drug category. As a TARGETED THERAPY, it is a humanized MONOCLONAL ANTIBODY that serves as an INTERCHANGEABLE BIOSIMILAR to the reference product Stelara. This means it has no clinically meaningful differences in safety, purity, or potency compared to the originator and can be substituted by a pharmacist without a new prescription from a healthcare provider (subject to state laws).

Starjemza is engineered to provide precise immune suppression for chronic inflammatory conditions. By neutralizing specific inflammatory proteins, it helps patients achieve long-term remission in debilitating diseases of the gut, skin, and joints.

• Generic Name: Ustekinumab-hmny
• US Brand Name: Starjemza
• Drug Class: Interleukin-12 (IL-12) and Interleukin-23 (IL-23) Antagonist
• Route of Administration: Intravenous (IV) Infusion (Induction) and Subcutaneous (SC) Injection (Maintenance)
• FDA Approval Status: FDA-approved (May 2025) and officially launched in the U.S. in November 2025.
  
  Get reliable medical facts about Starjemza. Classified as a Interleukin Inhibitor, this treatment is widely used for Ustekinumab biosimilar for IBD. Trust our hospital for your healthcare needs.

What Is It and How Does It Work? (Mechanism of Action)

Starjemza functions through SELECTIVE CYTOKINE INHIBITION, specifically targeting the p40 subunit shared by two key inflammatory cytokines: IL-12 and IL-23.

Molecular and Cellular Level Action

In healthy individuals, these cytokines help the body fight infections. However, in autoimmune diseases like Crohn’s or Psoriasis, they are overproduced, driving a cascade of inflammation that causes tissue damage.

1. Dual Blockade: Starjemza binds with high affinity to the p40 protein subunit. This subunit is a building block for both IL-12 and IL-23.
2. Receptor Interference: By “capping” the p40 subunit, the drug prevents IL-12 and IL-23 from binding to their receptor complexes (IL-12Rβ1) on the surface of immune cells (T-cells and Natural Killer cells).
3. Th1 and Th17 Pathway Suppression: This blockade prevents the maturation and activation of Th1 and Th17 cells. Without these signals, these cells cannot release the secondary cytokines that cause redness, swelling, and intestinal ulcers.
4. Prevention of Systemic Damage: By quieting this overarching inflammatory signal, Starjemza allows for mucosal healing in the gut and skin clearance, halting the systemic damage caused by chronic inflammation.

FDA-Approved Clinical Indications

Primary Indication

• Crohn’s Disease (CD): For the treatment of moderately to severely active CD in adult patients.
• Ulcerative Colitis (UC): For the treatment of moderately to severely active UC in adult patients.

Other Approved & Off-Label Uses

• Plaque Psoriasis (PsO): For adults and pediatric patients (6 years and older) with moderate-to-severe disease.
• Psoriatic Arthritis (PsA): For adults and pediatric patients (6 years and older) with active disease.

Primary Immunology Indications:

• B-Cell and T-Cell Modulation: Indirectly reducing B-cell autoantibody production by silencing the T-cell signals that drive them.
• Targeted Immunosuppression: Restoring immune balance in the gut and skin without causing the total body suppression associated with older steroids.

Dosage and Administration Protocols

Starjemza follows a “Load and Maintain” strategy for IBD, requiring an initial hospital-based infusion followed by home-based injections.

Dose Adjustments and Specific Populations:

• Pediatric Dosing: For psoriasis and PsA (6-17 years), dosing is based on weight ( \le  0.75 mg/kg for those under 60 kg).
• IV Preparation: The initial 130 mg/26 mL vials must be diluted and infused by a professional over at least one hour.
• Storage: Maintenance syringes must be refrigerated. They can be stored at room temperature for up to 30 days if needed, but should never be frozen.

Clinical Efficacy and Research Results

As a biosimilar, Starjemza’s efficacy is proven through “Analytical Similarity” and Phase 3 trials that demonstrated no clinically meaningful differences from Stelara.

Precise Numerical Data

• Crohn’s Response: In reference trials, approximately 56% of patients achieved clinical response by week 6 of induction.
• Remission Durability: Data through 2025–2026 confirms that over 53% of Crohn’s patients maintain remission through one full year of maintenance therapy.
• UC Clearance: In Ulcerative Colitis, roughly 45% of patients achieve clinical remission within the first year.
• Interchangeability: 2026 real-world data indicates that patients who switch from the originator to Starjemza maintain identical PASI (skin) and CDAI (Crohn’s) scores.

Safety Profile and Side Effects

Common Side Effects (>10%)

• Nasopharyngitis: Common cold symptoms.
• Headache: Usually mild and transient.
• Fatigue: Particularly following the IV infusion.

Serious Adverse Events

• Serious Infections: Increased risk of bacterial, fungal, or viral infections (e.g., TB reactivation).
• Malignancy: A theoretical increased risk of certain cancers, including non-melanoma skin cancers.
• Posterior Reversible Encephalopathy Syndrome (PRES): A rare but serious brain condition involving headache, seizures, or confusion.
• Noninfectious Pneumonia: Rare inflammation of the lungs.

Management Strategies:

• Pre-screening: Mandatory screening for Tuberculosis (TB) before the first dose.
• Vigilance: Patients are monitored for signs of PRES, which can occur days to months after starting treatment.

Research Areas

Direct Clinical Connections

Active research in 2026 is investigating the use of Robotic Pills (RT-111) to deliver ustekinumab biosimilars orally. Early Phase 1 data suggests that this delivery system can achieve bioavailability comparable to subcutaneous injections, potentially eliminating the need for needles in the future.

Generalization

The field of TARGETED THERAPY is currently focusing on “Dual-Targeted Therapy.” 2025–2026 trials are evaluating the safety of combining IL-23 inhibitors like Starjemza with newer oral JAK inhibitors for the most refractory cases of Ulcerative Colitis.

Severe Disease & Multi-Organ Involvement

Research is tracking Starjemza’s efficacy in preventing systemic damage in patients with “Psoriatic Disease,” an umbrella term for systemic inflammation affecting the heart, gut, and skin simultaneously. Studies are evaluating if early use of IL-12/23 blockers reduces the long-term risk of cardiovascular events.

Disclaimer: The research discussed regarding oral delivery systems (Robotic Pills), dual-targeted therapy combinations with JAK inhibitors, and the prevention of systemic cardiovascular events in psoriatic disease is currently in the investigational or early-phase clinical trial stage and is not yet applicable to practical or professional clinical scenarios. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: QuantiFERON-TB Gold test and Hepatitis B screening.
• Organ Function: Complete Blood Count (CBC) and Liver Function Tests (LFTs).
• Screening: Review of vaccination history. Live vaccines must be avoided.

Monitoring and Precautions

• Vigilance: Monitor for neurological changes (seizures, confusion) as signs of PRES.
• Lifestyle:
  • Sun Protection: Use high-SPF sunscreen as there is a slight increase in skin cancer risk.
  • Stress Management: Chronic stress can trigger IBD flares; yoga or mindfulness is encouraged.

Do’s and Don’ts for Immunocompromised Patients:

• DO rotate your injection sites (thigh, abdomen, or upper arm) to prevent skin irritation.
• DO report any new cough or fever to your doctor immediately.
• DO ensure your first dose (IV) is recorded accurately before starting home injections.
• DON’T receive “live” vaccines (like the nasal flu spray or MMR) while on therapy.
• DON’T share your pre-filled syringes with anyone else.
• DON’T stop the medication without a physician-guided plan, as “rebound” inflammation can be severe.

Legal Disclaimer

This guide is for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. STARJEMZA (ustekinumab-hmny) is a potent BIOLOGIC and must be managed by a qualified Gastroenterologist or Dermatologist. Always consult with your healthcare provider regarding the risks and benefits of TARGETED THERAPY. Never disregard professional medical advice based on information provided in this guide. Proper disposal of needles in a Sharps container is mandatory for home use.